UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
February 29, 2016
MAGELLAN HEALTH, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE |
|
1-6639 |
|
58-1076937 |
(State or Other Jurisdiction |
|
(Commission File |
|
(IRS Employer |
of Incorporation) |
|
Number) |
|
Identification No.) |
4800 SCOTTSDALE RD, SUITE 4400 |
|
|
SCOTTSDALE, ARIZONA |
|
85251 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (602) 572-6050
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition
On February 29, 2016, Magellan Health, Inc. (the Company) reported operating results for the quarter and full year ended December 31, 2015 and updated its guidance for 2016.
Attached and incorporated herein by reference as Exhibit 99.1 is a copy of the press release dated February 29, 2016.
Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibits
(a) Financial Statements of business acquired: Not applicable.
(b) Pro forma financial information: Not applicable.
(d) Exhibits:
Exhibit Number |
|
Description |
99.1 |
|
Registrants press release dated February 29, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MAGELLAN HEALTH, INC.
Date: February 29, 2016 |
By: |
/s/ Jonathan N. Rubin | |
|
|
Name: |
Jonathan N. Rubin |
|
|
Title: |
Executive Vice President and |
Exhibit 99.1
NEWS RELEASE
Media Contact: Colleen Flanagan Johnson, cefjohnson@magellanhealth.com, (860) 507-1923
Investor Contact: Renie Shapiro Silver, rshapiro@magellanhealth.com, (877) 645-6464
Magellan Health Reports Fourth Quarter and Full Year 2015 Financial Results
Revenue exceeds $4.5 billion for the first time
Scottsdale, Ariz. February 29, 2016 Magellan Health, Inc. (NASDAQ: MGLN) today reported financial results for the fourth quarter and full year of 2015, as summarized below. For the year ended December 31, 2015, the company reported net revenue of $4.60 billion, segment profit of $275.7 million, and net income of $31.4 million, or $1.21 per diluted common share. In addition, the company reported adjusted net income of $91.8 million and adjusted earnings per share of $3.55. As of December 31, 2015, the company had unrestricted cash and investments of $160.2 million.
Fourth Quarter and Full Year 2015 Results*
|
|
Three Months Ended |
|
Year Ended |
| ||||||||||||
|
|
December 31 |
|
December 31 |
| ||||||||||||
|
|
|
|
|
|
Inc/ |
|
|
|
|
|
Inc/ |
| ||||
(Millions, except per share results) |
|
2015 |
|
2014 |
|
(Dec) |
|
2015 |
|
2014 |
|
(Dec) |
| ||||
Net Revenue |
|
$ |
1,268.7 |
|
$ |
982.5 |
|
29.1 |
% |
$ |
4,597.4 |
|
$ |
3,760.1 |
|
22.3 |
% |
Segment Profit* |
|
102.2 |
|
83.2 |
|
22.8 |
% |
275.7 |
|
266.9 |
|
3.3 |
% | ||||
Adjusted Net Income* |
|
33.8 |
|
35.0 |
|
(3.4 |
)% |
91.8 |
|
110.6 |
|
(17.0 |
)% | ||||
Net Income |
|
27.3 |
|
21.6 |
|
26.4 |
% |
31.4 |
|
79.4 |
|
(60.5 |
)% | ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Per Share Results: |
|
|
|
|
|
|
|
|
|
|
|
|
| ||||
Adjusted Earnings per Share* |
|
1.39 |
|
1.33 |
|
4.5 |
% |
3.55 |
|
4.04 |
|
(12.1 |
)% | ||||
Earnings per Share |
|
1.12 |
|
0.82 |
|
36.6 |
% |
1.21 |
|
2.90 |
|
(58.3 |
)% | ||||
Variances for the three months ended December 31, 2015 versus December 31, 2014:
· The increase in revenue between periods resulted primarily from the inclusion of revenues from acquired entities, the impact of new business and same store growth, which were partially offset by the loss of revenues associated with contract terminations.
· The increase in segment profit between periods was primarily due to the net impact of favorable year-over-year medical claims development, new business, same store growth, strong specialty pharmacy earnings and the inclusion of 4D results in the current year quarter, which were partially offset by the impact of contract terminations, cost of care trends, and a higher level of favorable customer settlements and retroactive revenue adjustments in the prior year quarter. Included in segment profit
* Refer to the Basis of Presentation for a discussion of non-GAAP financial measures.
for the current year quarter are approximately $10 million of net favorable non-recurring items, mainly related to medical claims development in the healthcare segment.
· The decrease in adjusted net income between periods was mainly due to higher depreciation and amortization expense and a higher effective income tax rate in the current year quarter, partially offset by the increase in segment profit.
· The increase in net income was due to the items affecting adjusted net income described above, as well as a decrease in contingent consideration expense and stock compensation expense related to acquisitions.
We had a very strong fourth quarter and completed 2015 with segment profit, adjusted net income and adjusted EPS above our previous guidance range, surpassing $4.5 billion in revenue for the first time, said Barry M. Smith, chairman and chief executive officer of Magellan Health. Operationally, we made strong advances this year, consolidating into two businesses, strengthening our leadership team, developing new capabilities and further refining our MCC and pharmacy strategies.
Results and Outlook
Overall, Im very pleased with our fourth quarter 2015 results, and the progress we are making on our strategic initiatives. I believe this provides us with positive momentum as we begin 2016, said Jonathan N. Rubin, chief financial officer of Magellan Health.
The TMG acquisition is expected to close later today, and we anticipate that TMG will generate revenues during the last ten months of 2016 of approximately $40 million, with segment profit of approximately $3 million. The impact to adjusted net income and adjusted EPS is an increase of approximately $3 million, or $0.12 per share. The impact to net income and EPS in 2016 will not be material. We will be updating our guidance for 2016 to reflect this acquisition.
Earnings Conference Call
Management will host a conference call at 10:00 a.m. Eastern on Monday, February 29, 2016. To participate in the conference call, interested parties should call 1-800-857-1812 and reference the pass code Fourth Quarter 2015 Earnings Call approximately 15 minutes before the start of the call. The conference call will also be available via a live webcast at Magellans investor relations page at MagellanHealth.com.
About Magellan Health: Headquartered in Scottsdale, Ariz., Magellan Health, Inc. is a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare. Magellan develops innovative solutions that combine advanced analytics, agile technology and clinical excellence to drive better decision making, positively impact health outcomes and optimize the cost of care for the members we serve all within a customer-first culture. Magellans customers include health plans and other managed care organizations, employers, labor unions, various military and governmental agencies and third-party administrators. For more information, visit MagellanHealth.com.
Basis of Presentation
In addition to results determined under Generally Accepted Accounting Principles (GAAP), Magellan provides certain non-GAAP financial measures that management believes are useful in assessing the companys performance. Following is a description of these important non-GAAP measures.
Segment profit is equal to net revenues less the sum of cost of care, cost of goods sold, direct service costs and other operating expenses, and includes income from unconsolidated subsidiaries, but excludes segment profit or loss from non-controlling interests held by other parties, stock compensation expense, as well as changes in the fair value of contingent consideration recorded in relation to acquisitions.
Adjusted net income and adjusted earnings per share reflect certain adjustments made for acquisitions completed after January 1, 2013 to exclude non-cash stock compensation expense resulting from restricted stock purchases by sellers, as well as changes in the fair value of contingent consideration recorded in relation to acquisitions and amortization of identified acquisition intangibles.
Included in the tables issued with this press release are the reconciliations from non-GAAP measures to the corresponding GAAP measures.
Cautionary Statement
This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, the anticipated impact of the TMG acquisition on the companys financial results for the remainder of 2016, and strategy. These statements are based on managements analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words believes, anticipates, plans, expects, may, should, could, estimate, intend and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the companys customers to manage the healthcare services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the companys risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the Risk Factors section included within the companys Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission on March 3, 2014, and the companys subsequent Quarterly Reports on Form 10-Q filed during 2015. Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit, adjusted net income, and adjusted EPS information referred to herein may be considered a non-GAAP financial measure. Further information regarding these measures, including the reasons management considers this information useful to investors, are included in the companys most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.
###
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands, except per share amounts)
|
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
| ||||||||
|
|
2014 |
|
2015 (1) |
|
2014 |
|
2015 (1) |
| ||||
|
|
(unaudited) |
|
(unaudited) |
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Net revenue: |
|
|
|
|
|
|
|
|
| ||||
Managed care and other |
|
$ |
753,489 |
|
$ |
863,506 |
|
$ |
2,968,374 |
|
$ |
3,197,645 |
|
PBM and dispensing |
|
228,970 |
|
405,237 |
|
791,744 |
|
1,399,755 |
| ||||
Total net revenue |
|
982,459 |
|
1,268,743 |
|
3,760,118 |
|
4,597,400 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Costs and expenses: |
|
|
|
|
|
|
|
|
| ||||
Cost of care |
|
506,090 |
|
587,816 |
|
2,088,595 |
|
2,274,755 |
| ||||
Cost of goods sold |
|
212,905 |
|
381,817 |
|
732,949 |
|
1,321,877 |
| ||||
Direct service costs and other operating expenses (2)(3) |
|
202,814 |
|
205,901 |
|
723,498 |
|
822,392 |
| ||||
Depreciation and amortization |
|
24,405 |
|
27,605 |
|
91,070 |
|
102,844 |
| ||||
Interest expense |
|
1,668 |
|
1,648 |
|
7,387 |
|
6,581 |
| ||||
Interest income and other income |
|
(474 |
) |
(568 |
) |
(1,301 |
) |
(2,165 |
) | ||||
Total costs and expenses |
|
947,408 |
|
1,204,219 |
|
3,642,198 |
|
4,526,284 |
| ||||
Income before income taxes |
|
35,051 |
|
64,524 |
|
117,920 |
|
71,116 |
| ||||
Provision for income taxes |
|
15,305 |
|
39,543 |
|
43,689 |
|
42,409 |
| ||||
Net income |
|
19,746 |
|
24,981 |
|
74,231 |
|
28,707 |
| ||||
Less: net income (loss) attributable to non-controlling interest |
|
(1,819 |
) |
(2,309 |
) |
(5,173 |
) |
(2,706 |
) | ||||
Net income attributable to Magellan Health, Inc. |
|
$ |
21,565 |
|
$ |
27,290 |
|
$ |
79,404 |
|
$ |
31,413 |
|
|
|
|
|
|
|
|
|
|
| ||||
Weighted average number of common shares outstanding basic |
|
25,558 |
|
23,582 |
|
26,689 |
|
24,865 |
| ||||
Weighted average number of common shares outstanding diluted |
|
26,382 |
|
24,402 |
|
27,355 |
|
25,877 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Net income per common share attributable to Magellan Health, Inc. - basic |
|
$ |
0.84 |
|
$ |
1.16 |
|
$ |
2.98 |
|
$ |
1.26 |
|
Net income per common share attributable to Magellan Health, Inc. - diluted |
|
$ |
0.82 |
|
$ |
1.12 |
|
$ |
2.90 |
|
$ |
1.21 |
|
|
|
|
|
|
|
|
|
|
| ||||
Net income |
|
$ |
19,746 |
|
$ |
24,981 |
|
$ |
74,231 |
|
$ |
28,707 |
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
| ||||
Unrealized losses on available-for-sale securities (4) |
|
(52 |
) |
(148 |
) |
(50 |
) |
(119 |
) | ||||
Comprehensive income |
|
19,694 |
|
24,833 |
|
74,181 |
|
28,588 |
| ||||
Less: comprehensive income (loss) attributable to non-controlling interest |
|
(1,819 |
) |
(2,309 |
) |
(5,173 |
) |
(2,706 |
) | ||||
Comprehensive income attributable to Magellan Health, Inc. |
|
$ |
21,513 |
|
$ |
27,142 |
|
$ |
79,354 |
|
$ |
31,294 |
|
(1) For a more detailed discussion of Magellan Healths results for the year ended December 31, 2015, refer to the Companys Annual Report on Form 10-K, which will be filed with the SEC on Monday, February 29, 2016, and the live broadcast or taped replay of the Companys earnings conference call on Monday, February 29, 2016, which will be available at MagellanHealth.com.
(2) Includes stock compensation expense of $14,601 and $9,791 for the three months ended December 31, 2014 and 2015, respectively, and $40,584 and $50,384 for the years ended December 31, 2014 and 2015, respectively.
(3) Includes changes in fair value of contingent consideration of $6,172 and $(3,017) for the three months ended December 31, 2014 and 2015, respectively, and $6,172 and $44,257 for the years ended December 31, 2014 and 2015, respectively.
(4) Net of income tax benefit of $(34) and $(93) for the three months ended December 31, 2014 and 2015, respectively, and $(33) and $(68) for the years ended December 31, 2014 and 2015, respectively.
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
NON-GAAP MEASURES
(In thousands, except per share amounts)
|
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
| ||||||||
|
|
2014 |
|
2015 (1) |
|
2014 |
|
2015 (1) |
| ||||
|
|
(unaudited) |
|
(unaudited) |
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Adjusted net income |
|
$ |
35,043 |
|
$ |
33,771 |
|
$ |
110,555 |
|
$ |
91,775 |
|
Adjusted for acquisitions starting in 2013 |
|
|
|
|
|
|
|
|
| ||||
Stock compensation expense relating to acquisitions |
|
(11,398 |
) |
(6,476 |
) |
(27,594 |
) |
(32,235 |
) | ||||
Changes in fair value of contingent consideration |
|
(6,172 |
) |
3,017 |
|
(9,304 |
) |
(44,257 |
) | ||||
Amortization of acquired intangibles |
|
(4,320 |
) |
(5,740 |
) |
(13,696 |
) |
(21,371 |
) | ||||
Tax impact |
|
8,412 |
|
2,718 |
|
19,443 |
|
37,501 |
| ||||
Net income attributable to Magellan Health, Inc. |
|
$ |
21,565 |
|
$ |
27,290 |
|
$ |
79,404 |
|
$ |
31,413 |
|
|
|
|
|
|
|
|
|
|
| ||||
Adjusted EPS |
|
$ |
1.33 |
|
$ |
1.39 |
|
$ |
4.04 |
|
$ |
3.55 |
|
Adjusted for acquisitions starting in 2013 |
|
|
|
|
|
|
|
|
| ||||
Stock compensation expense relating to acquisitions |
|
(0.43 |
) |
(0.27 |
) |
(1.01 |
) |
(1.25 |
) | ||||
Changes in fair value of contingent consideration |
|
(0.24 |
) |
0.13 |
|
(0.34 |
) |
(1.71 |
) | ||||
Amortization of acquired intangibles |
|
(0.16 |
) |
(0.24 |
) |
(0.50 |
) |
(0.83 |
) | ||||
Tax impact |
|
0.32 |
|
0.11 |
|
0.71 |
|
1.45 |
| ||||
Net income per common share attributable to Magellan Health, Inc. - diluted |
|
$ |
0.82 |
|
$ |
1.12 |
|
$ |
2.90 |
|
$ |
1.21 |
|
(1) The Companys Annual Report on Form 10-K for the year ended December 31, 2015 will be filed with the SEC on Monday, February 29, 2016.
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
|
|
Year Ended December 31, |
| ||||
|
|
2014 |
|
2015 (1) |
| ||
|
|
|
|
|
| ||
Cash flows from operating activities: |
|
|
|
|
| ||
Net income |
|
$ |
74,231 |
|
$ |
28,707 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
| ||
Depreciation and amortization |
|
91,070 |
|
102,844 |
| ||
Non-cash interest expense |
|
3,987 |
|
399 |
| ||
Non-cash stock compensation expense |
|
40,584 |
|
50,384 |
| ||
Non-cash income tax benefit |
|
(4,291 |
) |
(26,990 |
) | ||
Non-cash amortization on investments |
|
5,050 |
|
7,118 |
| ||
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses: |
|
|
|
|
| ||
Restricted cash (2) |
|
21,371 |
|
81,728 |
| ||
Accounts receivable, net |
|
(74,604 |
) |
(52,394 |
) | ||
Pharmaceutical inventory |
|
10,234 |
|
(11,374 |
) | ||
Other assets |
|
(7,557 |
) |
4,149 |
| ||
Accounts payable and accrued liabilities |
|
5,887 |
|
(36,043 |
) | ||
Medical claims payable and other medical liabilities |
|
55,670 |
|
36,187 |
| ||
Contingent consideration |
|
|
|
55,035 |
| ||
Tax contingencies |
|
(14,955 |
) |
(1,030 |
) | ||
Deferred credits and other long-term liabilities |
|
4,045 |
|
294 |
| ||
Other |
|
322 |
|
171 |
| ||
Net cash provided by operating activities |
|
211,044 |
|
239,185 |
| ||
|
|
|
|
|
| ||
Cash flows from investing activities: |
|
|
|
|
| ||
Capital expenditures |
|
(62,337 |
) |
(71,584 |
) | ||
Acquisitions and investments in businesses, net of cash acquired |
|
(128,277 |
) |
(55,818 |
) | ||
Purchase of investments |
|
(340,961 |
) |
(470,093 |
) | ||
Maturity of investments |
|
276,446 |
|
404,308 |
| ||
Net cash used in investing activities |
|
(255,129 |
) |
(193,187 |
) | ||
|
|
|
|
|
| ||
Cash flows from financing activities: |
|
|
|
|
| ||
Proceeds from issuance of debt |
|
250,000 |
|
|
| ||
Payments to acquire treasury stock |
|
(197,533 |
) |
(206,044 |
) | ||
Proceeds from exercise of stock options and warrants |
|
52,994 |
|
53,493 |
| ||
Payments on long-term debt and capital lease obligations |
|
(8,045 |
) |
(17,038 |
) | ||
Payments on contingent consideration |
|
|
|
(20,762 |
) | ||
Tax benefit from exercise of stock options and vesting of stock awards |
|
3,218 |
|
4,073 |
| ||
Other |
|
(4,433 |
) |
409 |
| ||
Net cash provided by (used in) financing activities |
|
96,201 |
|
(185,869 |
) | ||
|
|
|
|
|
| ||
Net increase (decrease) in cash and cash equivalents |
|
52,116 |
|
(139,871 |
) | ||
Cash and cash equivalents at beginning of period |
|
203,187 |
|
255,303 |
| ||
Cash and cash equivalents at end of period |
|
$ |
255,303 |
|
$ |
115,432 |
|
(1) The Companys Annual Report on Form 10-K for the year ended December 31, 2015 will be filed with the SEC on Monday, February 29, 2016.
(2) Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change. During the year ended December 31, 2014 and 2015, restricted cash of $25,997 and $105,281, respectively, was shifted to restricted investments that resulted in an operating cash flow source.
MAGELLAN HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT
(In thousands)
|
|
Three Months Ended December 31, |
|
Twelve months Ended December 31, |
| ||||||||
|
|
2014 |
|
2015 (1) |
|
2014 |
|
2015 (1) |
| ||||
|
|
(unaudited) |
|
(unaudited) |
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Healthcare |
|
|
|
|
|
|
|
|
| ||||
Managed care and other net revenue |
|
$ |
697,585 |
|
$ |
788,891 |
|
$ |
2,780,905 |
|
$ |
2,959,252 |
|
Cost of care |
|
506,088 |
|
587,811 |
|
2,090,352 |
|
2,274,755 |
| ||||
Direct service costs and other |
|
114,754 |
|
113,324 |
|
420,092 |
|
438,019 |
| ||||
Stock compensation expense (2) |
|
(657 |
) |
(604 |
) |
(2,899 |
) |
(2,556 |
) | ||||
Changes in fair value of contingent consideration (2) |
|
(38 |
) |
766 |
|
(38 |
) |
1,404 |
| ||||
Non-controlling interest - segment profit (loss) (3) |
|
(1,786 |
) |
(2,121 |
) |
(5,087 |
) |
(2,439 |
) | ||||
Healthcare segment profit |
|
79,224 |
|
89,715 |
|
278,485 |
|
250,069 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Pharmacy Management |
|
|
|
|
|
|
|
|
| ||||
Managed Care and other net revenue |
|
55,904 |
|
74,628 |
|
205,524 |
|
238,456 |
| ||||
PBM and dispensing revenue |
|
254,397 |
|
433,092 |
|
844,512 |
|
1,510,180 |
| ||||
Cost of care |
|
2 |
|
5 |
|
16,298 |
|
|
| ||||
Cost of goods sold |
|
237,396 |
|
408,480 |
|
784,758 |
|
1,427,680 |
| ||||
Direct service costs and other |
|
60,142 |
|
58,431 |
|
182,833 |
|
265,661 |
| ||||
Stock compensation expense (2) |
|
(14,848 |
) |
(6,582 |
) |
(28,829 |
) |
(34,864 |
) | ||||
Changes in fair value of contingent consideration (2) |
|
(6,134 |
) |
2,251 |
|
(6,134 |
) |
(45,661 |
) | ||||
Pharmacy Management segment profit |
|
33,743 |
|
45,135 |
|
101,110 |
|
135,820 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Corporate and Other |
|
|
|
|
|
|
|
|
| ||||
Corporate and Other |
|
28,854 |
|
35,351 |
|
121,532 |
|
123,397 |
| ||||
Stock compensation expense (2) |
|
904 |
|
(2,605 |
) |
(8,856 |
) |
(12,964 |
) | ||||
Non-controlling interest - segment profit (loss) (3) |
|
|
|
(116 |
) |
|
|
(195 |
) | ||||
Corporate and Other (excluding eliminations) |
|
(29,758 |
) |
(32,630 |
) |
(112,676 |
) |
(110,238 |
) | ||||
|
|
|
|
|
|
|
|
|
| ||||
Eliminations (4) |
|
|
|
|
|
|
|
|
| ||||
Managed Care and other net revenue |
|
|
|
(13 |
) |
(18,055 |
) |
(63 |
) | ||||
PBM and dispensing revenue |
|
(25,427 |
) |
(27,855 |
) |
(52,768 |
) |
(110,425 |
) | ||||
Cost of care |
|
|
|
|
|
(18,055 |
) |
|
| ||||
Cost of goods sold |
|
(24,491 |
) |
(26,663 |
) |
(51,809 |
) |
(105,803 |
) | ||||
Corporate and other |
|
(936 |
) |
(1,205 |
) |
(959 |
) |
(4,685 |
) | ||||
Eliminations |
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Consolidated |
|
|
|
|
|
|
|
|
| ||||
Managed care and other net revenue |
|
753,489 |
|
863,506 |
|
2,968,374 |
|
3,197,645 |
| ||||
PBM and dispensing revenue |
|
228,970 |
|
405,237 |
|
791,744 |
|
1,399,755 |
| ||||
Cost of care |
|
506,090 |
|
587,816 |
|
2,088,595 |
|
2,274,755 |
| ||||
Cost of goods sold |
|
212,905 |
|
381,817 |
|
732,949 |
|
1,321,877 |
| ||||
Direct service costs and other |
|
202,814 |
|
205,901 |
|
723,498 |
|
822,392 |
| ||||
Stock compensation expense (2) |
|
(14,601 |
) |
(9,791 |
) |
(40,584 |
) |
(50,384 |
) | ||||
Changes in fair value of contingent consideration (2) |
|
(6,172 |
) |
3,017 |
|
(6,172 |
) |
(44,257 |
) | ||||
Non-controlling interest - segment profit (loss) (3) |
|
(1,786 |
) |
(2,237 |
) |
(5,087 |
) |
(2,634 |
) | ||||
Consolidated segment profit |
|
$ |
83,209 |
|
$ |
102,220 |
|
$ |
266,919 |
|
$ |
275,651 |
|
|
|
|
|
|
|
|
|
|
| ||||
Reconciliation of segment profit to income before income taxes: |
|
|
|
|
|
|
|
|
| ||||
Segment profit |
|
$ |
83,209 |
|
$ |
102,220 |
|
$ |
266,919 |
|
$ |
275,651 |
|
Stock compensation expense |
|
(14,601 |
) |
(9,791 |
) |
(40,584 |
) |
(50,384 |
) | ||||
Changes in fair value of contingent consideration |
|
(6,172 |
) |
3,017 |
|
(6,172 |
) |
(44,257 |
) | ||||
Non-controlling interest segment profit (loss) |
|
(1,786 |
) |
(2,237 |
) |
(5,087 |
) |
(2,634 |
) | ||||
Depreciation and amortization |
|
(24,405 |
) |
(27,605 |
) |
(91,070 |
) |
(102,844 |
) | ||||
Interest expense |
|
(1,668 |
) |
(1,648 |
) |
(7,387 |
) |
(6,581 |
) | ||||
Interest and other income |
|
474 |
|
568 |
|
1,301 |
|
2,165 |
| ||||
Income before income taxes |
|
$ |
35,051 |
|
$ |
64,524 |
|
$ |
117,920 |
|
$ |
71,116 |
|
(1) The Companys Annual Report on Form 10-K for the year ended December 31, 2015 will be filed with the SEC on Monday, February 29, 2016.
(2) Stock compensation expense, as well as changes in the fair value of contingent consideration recorded in relation to the acquisitions, are included in direct service costs and other operating expenses; however, these amounts are excluded from the computation of segment profit.
(3) The non-controlling portion of AlphaCares segment profit (loss) is excluded from the computation of segment profit.
(4) Healthcare subcontracts with Pharmacy Management to provide pharmacy benefits management services for certain of Healthcares customers. In addition, Pharmacy Management provides pharmacy benefits management for the Companys employees covered under its medical plan. As such, revenue, cost of goods sold and direct service costs and other related to these arrangements are eliminated.
CT5R_
MBCX@Z/X5D2"[:2:[=0WD0C+ 'H3V%5_#7Q,T;Q)?BQC$UK=O]R.=0-_L"._M
M0!=N/&^G6WBZ+PZ\=P;V3;A@@V